Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
10Customers
1Debt Items
6Related Chains
Source-Backed Evidence Depth
Impact BioMedical Inc. (IBO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
19Total relationships
3Distinct source URLs
16High confidence
0.837Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Impact BioMedical Inc. Suppliers
Ticker
Name
Confidence
Evidence
DSS-INC
DSS-INC
92%
In consideration thereof, PubCo agreed to issue to DSS, Inc. the DSS Shares at the Closing, subject to the effectiveness of the registration statement covering such shares.
CHEMIA
CHEMIA
90%
Based on the Addendum, Chemia should pay the Company 5 % of net sales in royalty.
DSS-BIOHEALTH-SECURITY-INC
DSS-BIOHEALTH-SECURITY-INC
85%
Schedule I was amended to reflect the updated share ownership of DSS, Inc. and DSS BioHealth Security, Inc.
GRDG-SCIENCES-LLC
GRDG-SCIENCES-LLC
80%
Licensing Proceeds Distribution Agreement with GRDG Sciences, LLC dated February 15, 2022
Reciprocal relationship from DSS graph: ating segments in 2024 highlight the company’s ongoing commitment to innovation and diversification. Each segment is strategically positioned for growth, with …
Impact BioMedical Inc. Customers
Ticker
Name
Confidence
Evidence
DSS-INC
DSS-INC
92%
DSS, Inc. agreed to certain funding and hold harmless obligations in connection with the transactions contemplated by the Merger and Share Exchange Agreement
CHEMIA
CHEMIA
90%
Based on the Addendum, Chemia should pay the Company 5 % of net sales in royalty.
Reciprocal relationship from PRPH graph: Reciprocal relationship from IBO graph: Reciprocal relationship from PRPH graph: Reciprocal relationship from IBO graph: In exchange, the Licensee shall pay t…
In exchange, the Licensee shall pay the Company a royalty of 5.5 % of net sales.
DSS-BIOHEALTH-SECURITY-INC
DSS-BIOHEALTH-SECURITY-INC
85%
Schedule I was amended to reflect the updated share ownership of DSS, Inc. and DSS BioHealth Security, Inc.
DSS-PURE-AIR-INC
DSS-PURE-AIR-INC
85%
uired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised v…
LICENSEE
LICENSEE
85%
In exchange, the Licensee shall pay the Company a royalty of 5.5 % of net sales.
GRDG-SCIENCES-LLC
GRDG-SCIENCES-LLC
80%
The Company shall reimburse the Licensee for 50 % of the development costs provided that the development costs shall not exceed $ 1,250,000 .
Reciprocal relationship from DSS graph: ating segments in 2024 highlight the company’s ongoing commitment to innovation and diversification. Each segment is strategically positioned for growth, with …
CORPORATE-HISTORY-IMPACT-BIOMEDICAL-INC
CORPORATE-HISTORY-IMPACT-BIOMEDICAL-INC
62%
hod, and design patents. Trademarks: We have several trademarks related to Impact BioMedical. Websites: The primary corporate website we maintain is www.impactbiomedinc.com . Markets and Competition …
Impact BioMedical Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IBO-DEBT
Debt stack $11.9M
90%
Market cache reports total debt of $11.9M.
Impact BioMedical Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Impact BioMedical Inc..
Impact BioMedical Inc. Ownership
Holder
Name
Confidence
Evidence
IBO-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 22 tracked holders.
Impact BioMedical Inc. Extended Supply Chain Network
